Diabetes drug tested as potential cancer fighter
NCT ID NCT02437656
Summary
This study tested whether adding the common diabetes drug metformin to standard pre-surgery chemoradiation could improve treatment for locally advanced rectal cancer. It involved 60 patients who received metformin alongside their standard radiation and chemotherapy before surgery. The main goal was to see if this combination led to a complete disappearance of tumor cells in the surgically removed tissue.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Galilée - Hôpital Privé La Louvière
Lille, 59045, France
-
Centre Gray
Maubeuge, 59600, France
-
Centre Hospitalier
Lens, 62300, France
-
Centre Joliot-Curie
Saint-Martin-Boulogne, 62200, France
-
Centre Léonard de Vinci - SARL du pont Saint Vaast
Douai, 59500, France
-
Centre Marie Curie
Arras, 62000, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Centre Pierre Curie
Beuvry, 62880, France
-
Clinique des Dentellières
Valenciennes, 59300, France
-
Clinique du Bois - Centre Bourgogne
Lille, 59000, France
-
Institut André Dutreix
Dunkirk, 59240, France
Conditions
Explore the condition pages connected to this study.